Navigation Links
Sarasota's Roskamp Institute Announces Positive Safety Data in,Human Clinical Study for Alzheimer's Disease

And Japanese Study Suggests the Drug Improves Memory

SARASOTA, Fla., March 22, 2007 /PRNewswire-FirstCall/ -- The Roskamp Institute announced today that it has received positive preliminary results in its major clinical study that is testing a promising new drug application for the treatment of Alzheimer's disease. The clinical study, which was first announced in September, is the first human clinical study conducted by a Florida-based research institute as a result of its own original research. Today's announcement also highlighted achievements with the same drug in studies in Japan.

The drug, Nilvadipine, has not shown any major side effects in Alzheimer's disease patients during the initial six months of the study that is being conducted in partnership with the Trinity College Institute of Neuroscience in Dublin, Ireland. "This is a good indication that this drug will be safe in patients with Alzheimer's disease," said Dr. Michael Mullan, Director of the Roskamp Institute. "A staggering number of drugs fail once they go through their clinical studies due to safety issues. After treating more than a dozen Alzheimer patients with Nilvadipine, we can continue our studies because we have seen no serious side effects related to the drug."

This pilot study was the first step in trying to develop a potential treatment for Alzheimer's disease, and if it continues to be a success, could change the direction of other studies of dementia. In pre-clinical studies on mice, Nilvadipine was found to decrease the levels in the brain of a protein called beta amyloid. It is the presence of beta amyloid in the brain that is believed to cause the onset of Alzheimer's. The drug was also found to increase the flow of blood to the brain, which is believed to be beneficial in the treatment of the disease. The purpose of the study has been to determine whether the drug would have the same effect on humans suffering fro
'"/>




Page: 1 2

Related medicine technology :

1. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
2. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
3. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
4. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
5. Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting
6. Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:12/4/2009)... Calif., Dec. 4 Suneva Medical, a privately-held aesthetic ... Ranker as Vice President and Chief Financial Officer. ... Medical,s general and administrative functions including finance, accounting, IT, ... serve on the Company,s senior management team. ,, ...
(Date:12/4/2009)... TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced ... Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected ... across the country. The grand prize is an in-person meeting ... type 1 diabetes like Nick, are: Caleb, age 6, from ...
(Date:12/4/2009)... anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder ... the comorbidities reported to occur more often in ... epilepsy versus those without an epilepsy diagnosis, according ... the U.S. ,, Findings from " CNS-Related Comorbidities ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 1Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 2Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 3New research discovers link between smoking and brain damage 49757 1New research discovers link between smoking and brain damage 49757 2NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 1NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 2NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 3NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 4NIH expands Human Microbiome Project 3B funds sequencing centers and disease projects 8963 5
... BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - HepaLife Technologies, ... announced that new,data presented at an international ... cell line outperforms,current cell technologies at replicating ... important step towards the production of,a cell-culture ...
... WIRE)--Jun 25, 2007 - Pfizer announced today,that Lipitor ... stroke, coronary heart disease events and major coronary ... known coronary heart disease,but who had experienced a ... are from a new analysis of the landmark,Stroke ...
Other Medicine Technology:HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 2Lipitor Reduced the Risk of Coronary Events by Half and Stroke by,Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who,Experienced a Recent Stroke 3
(Date:12/6/2009)... that the loss of a key segment of DNA can ... to show that this kind of genetic alteration can cause ... , The study, led by Dr Sadaf Farooqi from the ... Trust Sanger Institute, looked at 300 children with severe obesity. ... types of mutation known as copy number variants (CNVs). CNVs ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... pivotal Phase 2b 003-A1 study, known as the ... heavily pre-treated relapsed and refractory multiple myeloma patients. ... Joint Symposium at the 51st annual meeting of ... Orleans. Enrollment in this trial is complete (n=269), ...
(Date:12/6/2009)... Sleep Disorders information and Treatment site www.sleeping-with-a-sleeping-disorder.com ... problems with herbal or natural sleep aids from ... remedies for a good cause. The submissions will ... Sleep Aids ,Encyclopedia, by YOU, to be sold ... site will donate 100% of the proceeds ,from ...
(Date:12/5/2009)... significant scientific advances in the field of blood cancers, ... of how certain diseases progress in order to discover ... care. Research presented today at the 51st Annual Meeting ... therapies for managing multiple myeloma, the importance of advance ...
(Date:12/5/2009)... and myeloproliferative disorders are serious and often deadly ... Annual Meeting of the American Society of Hematology ... methods for patients suffering from acute promyelocytic leukemia, ... myelofibrosis that are based on a better understanding ...
Breaking Medicine News(10 mins):Health News:Genetic studies reveal new causes of severe obesity in childhood 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Donate a Herbal Natural Sleep Aid to the Internet's First "Natural Sleep Aids E-book" Written by People Just Like You 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... been known that countries with rapidly developing economies may ... overnutrition. People living in poverty experience diseases that result ... suffer from diseases that result from an abundance of ... Health (HSPH) and the University of Bristol have examined ...
... beating heart could be new screening tool , TUESDAY, Sept. ... the hearts of pre-diabetic people before either diabetes or heart ... at the University of Texas Southwestern Medical Center discovered the ... a new screening tool for people at risk for diabetes ...
... Md., Sept. 4 Martek,s life,sDHA(TM),from microalgae ... triglycerides in male,hypertriglyceridemic patients, according to a ... American Journal of Clinical Nutrition. In this ... EPA,(eicosapentaenoic acid), the other omega 3 commonly ...
... destroys,enamel, CHICAGO, Sept. 4 Fruit, yogurt, citric ... but improper,consumption and overuse may lead to devastating and ... an online member poll conducted by,the Academy of General ... common today compared to five years ago., To ...
... withhold drugs because of side effect concerns, study finds , ... safety of asthma drugs may prevent asthmatic children from getting ... to data released in the September issue of Pediatrics ... more concerned about the side effects of asthma medications than ...
... Marlabs, Inc. has been named by,the Brown-Wilson Group ... Top 10 BPO,healthcare revenue cycle management companies. ... outsourcing users and,decision makers globally, garnering over 21,000 ... CEO Siby Vadakekkara attributes the recognition to their,commitment ...
Other Medicine News:Health News:Income inequality associated with overnourishment and undernourishment in India 2Health News:Fat Builds Up in Hearts Before Diabetes Onset 2Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 2Health News:Study Demonstrates Martek's Algal DHA Oil Improves Blood Triglyceride Lipid Levels 3Health News:Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion 2Health News:Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion 3Health News:Parents' Worries Hamper Kids' Asthma Treatment 2Health News:Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: